<DOC>
	<DOCNO>NCT00114140</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving temozolomide together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give temozolomide together radiation therapy work treat patient low-grade glioma .</brief_summary>
	<brief_title>Temozolomide Radiation Therapy Treating Patients With Gliomas</brief_title>
	<detailed_description>OBJECTIVES : - Compare 3-year survival patient high-risk low-grade glioma treat temozolomide radiotherapy follow temozolomide alone patient enrol European Organization Research Treatment Cancer ( EORTC ) clinical trial EORTC-22844 EORTC-22845 . - Determine toxicity regimen patient . - Determine association progression-free survival O6-methylguanine-DNA methyltransferase ( MGMT ) methylation status patient treat regimen . - Determine association survival MGMT methylation status patient treat regimen . - Determine quality life ( QOL ) patient treat regimen . - Determine neurocognitive function patient treat regimen . - Evaluate feasibility collect patient-reported QOL neurocognitive assessment 3 year . OUTLINE : This non-randomized , multicenter study . Patients receive oral temozolomide daily day 1-42 undergo radiotherapy daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 . Beginning 28 day completion chemoradiotherapy , patient receive oral temozolomide daily day 1-5 . Treatment temozolomide repeat every 28 day 12 course absence disease progression unacceptable toxicity . Quality life assess periodically 36 month . After completion study treatment , patient follow 4 month , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 135 patient accrue study within 44 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* supratentorial glioma 1 follow histology : Astrocytoma ( diffuse fibrillary , protoplasmic , gemistocytic ) Oligodendroglioma Oligoastrocytoma NOTE : *Histologic atypia allow provide histologic feature ( i.e. , frequent mitoses , endothelial proliferation , and/or acute necrosis ) would result designation anaplastic astrocytoma , anaplastic mixed oligodendroglioma oligoastrocytoma , glioblastoma multiforme present Unifocal multifocal disease WHO grade II disease Neurofibromatosis allow Surgical biopsy resection tumor tissue sampling require within past 12 week Tissue block core biopsy available O6methylguanineDNA methyltransferase analysis tissue banking Patients stereotactic biopsy eligible Must ≥ 3 follow risk factor : Age 40 Largest preoperative tumor diameter ≥ 6 cm Tumor cross midline Astrocytomadominant tumor subtype Preoperative Neurological Function Status &gt; 1 No lowgrade glioma histology , include follow : Pilocytic astrocytoma Subependymal giant cell astrocytoma tuberous sclerosis Subependymoma Pleomorphic xanthoastrocytoma Presence neuronal element , ganglioglioma Dysneuroembryoplastic epithelial tumor No highgrade glioma , include follow : Anaplastic astrocytoma Glioblastoma multiforme Anaplastic oligodendroglioma Anaplastic oligoastrocytoma No tumor nonsupratentorial location , include follow : Optic chiasm Optic nerve ( ) Pons Medulla Cerebellum Spinal cord No evidence disease progression spinal meninges noncontiguous cranial meninges ( i.e. , leptomeningeal gliomatosis ) MRI spine cerebrospinal fluid ( CSF ) cytology MRI spine CSF cytology require patient without symptom spinal/cranial meningeal disease progression PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Total bilirubin ≤ 1.5 mg/dL Serum glutamate oxaloacetate transaminase ( SGOT ) Serum glutamate pyruvate transaminase ( SGPT ) ≤ 2 time normal Alkaline phosphatase ≤ 2 time normal Renal Serum creatinine ≤ 1.5 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity No malignancy within past 5 year except carcinoma situ cervix nonmelanoma skin cancer No active infection PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy biologic therapy Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy head neck unless head neck radiotherapy clearly exclude brain ( e.g. , localized radiotherapy vocal cord ) No prior radiotherapy brain No concurrent intensity modulate radiotherapy No concurrent stereotactic boost radiotherapy Surgery See Disease Characteristics Other No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>